Radius Health, Inc.
NASDAQ:RDUS
16.4 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Radius Health, Inc. |
Symbool | RDUS |
Munteenheid | USD |
Prijs | 16.4 |
Beurswaarde | 456,567,800 |
Dividendpercentage | 3.85% |
52-weken bereik | 12.69 - 31.7 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Jesper Hoiland |
Website | https://radiuspharm.com |
An error occurred while fetching data.
Over Radius Health, Inc.
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)